INCB059872

DRUG4 trials

Sponsors

Incyte Corporation

Conditions

Advanced MalignanciesMetastatic CancerRelapsed Ewing SarcomaSickle Cell DiseaseSolid TumorsSolid Tumors and Hematologic Malignancy

Phase 1

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

TerminatedNCT02712905

Incyte CorporationSolid Tumors and Hematologic Malignancy

Start: 2016-05-05End: 2022-04-14Updated: 2025-11-04

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

TerminatedNCT02959437

Incyte CorporationAdvanced Malignancies, Metastatic Cancer, Solid Tumors

Start: 2017-02-27End: 2020-03-02Updated: 2025-10-21

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

TerminatedNCT03132324

Incyte CorporationSickle Cell Disease

Start: 2017-04-20End: 2018-10-03Updated: 2019-10-28

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

TerminatedNCT03514407

Incyte CorporationRelapsed Ewing Sarcoma

Start: 2018-06-27End: 2020-06-25Updated: 2025-10-21